Here, we report a novel multikinase inhibitor, designated as LL6, which has broad antitumor effects on non-small cell lung cancer (NSCLC) cells, including those carrying de novo or acquired resistance to chemotherapy or EGFR TKIs, both in vitro and in vivo, by concurrently targeting IGF-1R, Src, and AXL. Here, AXL is linked to non-small cell lung carcinoma.